18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors

Background: Immune checkpoint inhibitors (ICI) are currently the first-line treatment for patients with metastatic melanoma. We investigated the value of positron emission tomography (PET) response criteria to assess the therapeutic response to first-line ICI in this clinical context and explore the...

Full description

Bibliographic Details
Main Authors: Alexia Rivas, Julie Delyon, Antoine Martineau, Estelle Blanc, Clara Allayous, Laetitia Da Meda, Pascal Merlet, Céleste Lebbé, Barouyr Baroudjian, Laetitia Vercellino
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
FDG PET
melanoma
immunotherapy
therapeutic response
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/14/13/3190

Internet

https://www.mdpi.com/2072-6694/14/13/3190

Similar Items